Supplementary Figure 1. Prognostic value of peripheral naïve CD8+ T cells in oligometastatic non-small cell lung cancer

Representative flow cytometry plots and gating

Supplementary Figure 1. Prognostic value of peripheral naïve CD8+ T cells in oligometastatic non-small cell lung cancer

Representative flow cytometry plots and gating

Supplementary Figure 2. Prognostic value of peripheral naïve CD8+ T cells in oligometastatic non-small cell lung cancer

Overall survival and progression-free survival of patients with oligometastatic non-small cell lung cancer according to high and low values of naïve CD8+ T cells in patients treated with radiotherapy (A, B) and radiotherapy + chemotherapy or targeted therapy (C, D).

Abstract

Aim: This study aimed to investigate the prognostic value of peripheral naïve and memory CD8+ and CD4+ T cells and other immune cells in patients with oligometastatic non-small cell lung cancer (NSCLC) undergoing radiotherapy (RT).

Methods: A total of 142 patients with oligometastatic NSCLC treated with RT were enrolled, and their blood samples were collected within 3 days before RT. Immune cells were identified by flow cytometry.

Results: Patients with high levels of naïve CD8+ T cells had longer overall survival (OS; p = 0.004) and progression-free survival (PFS; p = 0.001) than those with low levels of naïve CD8+ T cells. Multivariate analyses revealed that naïve CD8+ T cells were independently correlated with OS (p = 0.019) and PFS (p = 0.024).

Conclusions: The results suggest that peripheral naïve CD8+ T cells may be an independent prognostic indicator for patients with oligometastatic NSCLC undergoing RT.